Diffuse large B-cell non-Hodgkin's lymphoma: ESMO Clinical Recommendations for diagnosis, treatment and follow-up

被引：28
|
作者：
Tilly, H. [1 ]
Dreyling, M. [2 ]
机构：
[1] Ctr Henry Becquerel, Dept Hematol, Rouen, France
[2] Ludwig Maximilians Univ Munchen, Univ Hosp Grosshadern, Dept Med 3, Munich, Germany
来源：
ANNALS OF ONCOLOGY | 2009年 / 20卷
关键词：
CHEMOTHERAPY PLUS RITUXIMAB; RANDOMIZED CONTROLLED-TRIAL; ELDERLY-PATIENTS; CHOP CHEMOTHERAPY; TRANSPLANTATION; THERAPY;
D O I：
10.1093/annonc/mdp145
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
[No abstract available]
引用
收藏
页码：110 / 112
页数：3
相关论文
共 50 条
  • [41] A phase II study of a modified hyper-CVAD frontline therapy for patients with adverse risk diffuse large B-cell and peripheral T-cell non-Hodgkin lymphoma
    Hapgood, Greg
    Stone, Janey M.
    Zannino, Diana
    George, Anup
    Marlton, Paula
    Prince, Henry Miles
    Hui, Chi-Hung
    Prosser, Ian
    Lewis, Ian D.
    Bradstock, Kenneth
    Seymour, John F.
    LEUKEMIA & LYMPHOMA, 2019, 60 (04) : 904 - 911
  • [42] Concentration and Glycoform of Rituximab in Plasma of Patients with B Cell Non-Hodgkin's Lymphoma
    Yonezawa, Atushi
    Otani, Yuki
    Kitano, Toshiyuki
    Mori, Mayuko
    Masui, Sho
    Isomoto, Yui
    Tsuda, Masahiro
    Imai, Satoshi
    Ikemi, Yasuaki
    Denda, Masaya
    Sato, Yuki
    Nakagawa, Shunsaku
    Omura, Tomohiro
    Nakagawa, Takayuki
    Yano, Ikuko
    Hayakari, Makoto
    Takaori-Kondo, Akifumi
    Matsubara, Kazuo
    PHARMACEUTICAL RESEARCH, 2019, 36 (06)
  • [43] Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
    Harousseau, J. -L.
    Dreyling, M.
    ANNALS OF ONCOLOGY, 2010, 21 : v155 - v157
  • [44] Limited Benefit of Routine Clinical Follow-Up for Relapse Detection in Diffuse Large B-Cell Lymphoma Patients in Complete Remission Following First-Line Treatment
    Lassen, Therese
    Nielsen, Torsten H.
    von Heymann, Annika
    Nielsen, Lene K.
    Larsen, Morten K.
    Gang, Anne O.
    Johansen, Christoffer
    Pedersen, Lars M.
    AMERICAN JOURNAL OF HEMATOLOGY, 2025, 100 (03) : 408 - 416
  • [45] Successful Treatment of a Patient Presenting with Simultaneous Diffuse Large B-Cell Lymphoma and Hodgkin Lymphoma: A Case Report
    Lee, Jungmin
    Han, Man Hoon
    Baek, Dong Won
    AMERICAN JOURNAL OF CASE REPORTS, 2025, 26
  • [46] Clinical features of diffuse large B-cell lymphoma with polyploidy
    Shimono, Joji
    Miyoshi, Hiroaki
    Seto, Masao
    Teshima, Takanori
    Ohshima, Koichi
    PATHOLOGY INTERNATIONAL, 2017, 67 (01) : 17 - 23
  • [47] Optimization of Rituximab for the Treatment of Diffuse Large B-Cell Lymphoma (II): Extended Rituximab Exposure Time in the SMARTE-R-CHOP-14 Trial of the German High-Grade Non-Hodgkin Lymphoma Study Group
    Pfreundschuh, Michael
    Poeschel, Viola
    Zeynalova, Samira
    Haenel, Mathias
    Held, Gerhard
    Schmitz, Norbert
    Viardot, Andreas
    Dreyling, Martin H.
    Hallek, Michael
    Mueller, Carsten
    Wiesen, Martin H. J.
    Witzens-Harig, Mathias
    Truemper, Lorenz
    Keller, Ulrich
    Rixecker, Tanja
    Zwick, Carsten
    Murawski, Niels
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (36) : 4127 - U354
  • [48] Impact of rituximab on treatment outcomes of patients with diffuse large b-cell lymphoma: a population-based analysis
    Lee, Linda
    Crump, Michael
    Khor, Sara
    Hoch, Jeffrey S.
    Luo, Jin
    Bremner, Karen
    Krahn, Murray
    Hodgson, David C.
    BRITISH JOURNAL OF HAEMATOLOGY, 2012, 158 (04) : 481 - 488
  • [49] Population pharmacokinetics of rituximab in patients with diffuse large B-cell lymphoma and association with clinical outcome
    Rozman, Samo
    Grabnar, Iztok
    Novakovic, Srdjan
    Mrhar, Ales
    Novakovic, Barbara Jezersek
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2017, 83 (08) : 1782 - 1790
  • [50] Evaluating surveillance imaging for diffuse large B-cell lymphoma and Hodgkin lymphoma
    Cohen, Jonathon B.
    Behera, Madhusmita
    Thompson, Carrie A.
    Flowers, Christopher R.
    BLOOD, 2017, 129 (05) : 561 - 564
12345